DE69332624T2 - WUNDHEILMITTEL UND BEHANDLUNG VON FIBROTISCHEN STORUNGEN DURCH TGFbeta-3 - Google Patents

WUNDHEILMITTEL UND BEHANDLUNG VON FIBROTISCHEN STORUNGEN DURCH TGFbeta-3

Info

Publication number
DE69332624T2
DE69332624T2 DE69332624T DE69332624T DE69332624T2 DE 69332624 T2 DE69332624 T2 DE 69332624T2 DE 69332624 T DE69332624 T DE 69332624T DE 69332624 T DE69332624 T DE 69332624T DE 69332624 T2 DE69332624 T2 DE 69332624T2
Authority
DE
Germany
Prior art keywords
tgfbeta
treatment
wound
wound medication
fibrous disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69332624T
Other languages
English (en)
Other versions
DE69332624D1 (de
Inventor
Mark William James Ferguson
Mamta Shah
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Renovo Ltd
Original Assignee
Renovo Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Renovo Ltd filed Critical Renovo Ltd
Publication of DE69332624D1 publication Critical patent/DE69332624D1/de
Application granted granted Critical
Publication of DE69332624T2 publication Critical patent/DE69332624T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69332624T 1992-03-28 1993-03-22 WUNDHEILMITTEL UND BEHANDLUNG VON FIBROTISCHEN STORUNGEN DURCH TGFbeta-3 Expired - Lifetime DE69332624T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929206861A GB9206861D0 (en) 1992-03-28 1992-03-28 Wound healing and treatment of fibrotic disorders
PCT/GB1993/000586 WO1993019769A1 (en) 1992-03-28 1993-03-22 Wound healing and treatment of fibrotic disorders

Publications (2)

Publication Number Publication Date
DE69332624D1 DE69332624D1 (de) 2003-02-13
DE69332624T2 true DE69332624T2 (de) 2003-10-02

Family

ID=10713078

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69332624T Expired - Lifetime DE69332624T2 (de) 1992-03-28 1993-03-22 WUNDHEILMITTEL UND BEHANDLUNG VON FIBROTISCHEN STORUNGEN DURCH TGFbeta-3

Country Status (19)

Country Link
US (1) US6331298B1 (de)
EP (1) EP0646012B1 (de)
JP (2) JP3919212B2 (de)
AT (1) ATE230605T1 (de)
AU (1) AU673161B2 (de)
BR (1) BR9306226A (de)
CA (1) CA2131383C (de)
CZ (1) CZ236694A3 (de)
DE (1) DE69332624T2 (de)
DK (1) DK0646012T3 (de)
ES (1) ES2189790T3 (de)
GB (1) GB9206861D0 (de)
HU (1) HUT68905A (de)
NO (1) NO943466L (de)
NZ (1) NZ249937A (de)
PT (1) PT646012E (de)
RU (1) RU94042387A (de)
SK (1) SK116894A3 (de)
WO (1) WO1993019769A1 (de)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9106678D0 (en) * 1991-03-28 1991-05-15 Ferguson Mark W J Wound healing
US7384634B2 (en) * 1991-08-30 2008-06-10 University Of South Florida Connective tissue growth factor
US5411940A (en) * 1993-09-29 1995-05-02 Alcon Laboratories, Inc. Use of TGF-β3 to reduce the formation of scar tissue in response to corneal trauma
EP0670733A1 (de) * 1993-09-29 1995-09-13 Alcon Laboratories, Inc. Zusammensetzungen welche wachstumsfaktoren und antineoplastische mitteln enthalten
US5449671A (en) * 1993-09-29 1995-09-12 Alcon Laboratories, Inc. Use of TGF-β3, to prevent or retard fistula closure following glaucoma filtration surgery
WO1995026203A1 (en) * 1994-03-29 1995-10-05 The Victoria University Of Manchester Wound healing
GB2288118A (en) * 1994-03-29 1995-10-11 Univ Manchester Wound healing composition
US5621093A (en) * 1995-06-06 1997-04-15 Anika Research, Inc. Steam-sterilizing solid hyaluronic acid
GB2304045A (en) * 1995-08-04 1997-03-12 Univ Manchester Betaglycan compositions for promoting the healing of wounds and fibrotic diseases
GB2304047A (en) 1995-08-09 1997-03-12 Univ Manchester Pharmaceutical compositions containing cytokines
GB2306481A (en) 1995-10-21 1997-05-07 Univ Manchester Pharmaceutical comprising a stimulator of activin and/or inhibin
PT941108E (pt) * 1996-12-04 2003-01-31 Renovo Ltd Cicatrizacao de feridas e tratamento da fibrose
US8017395B2 (en) 2004-12-17 2011-09-13 Lifescan, Inc. Seeding cells on porous supports
AU2006202209B2 (en) 2005-05-27 2011-04-14 Lifescan, Inc. Amniotic fluid derived cells
SI1888123T1 (sl) * 2005-06-08 2013-04-30 Janssen Biotech, Inc. Celična terapija za okularno degeneracijo
GB0514262D0 (en) * 2005-07-12 2005-08-17 Renovo Ltd Promotion of epithelial regeneration
US20070122448A1 (en) * 2005-11-28 2007-05-31 Alireza Rezania Compositions and methods to create a vascularized environment for cellular transplantation
GB0604938D0 (en) 2006-03-11 2006-04-19 Renovo Ltd Proteins, nucleic acids and medicaments
GB0604964D0 (en) * 2006-03-11 2006-04-19 Renovo Ltd Protein folding
GB0604966D0 (en) * 2006-03-11 2006-04-19 Renovo Ltd Medicaments and proteins
ES2725601T3 (es) 2006-04-28 2019-09-25 Lifescan Inc Diferenciación de células madre embriónicas humanas
US8741643B2 (en) 2006-04-28 2014-06-03 Lifescan, Inc. Differentiation of pluripotent stem cells to definitive endoderm lineage
GB0617816D0 (en) * 2006-09-11 2006-10-18 Renovo Ltd Nucleic acids and methods of protein expression
EP2091557A2 (de) 2006-11-15 2009-08-26 Coda Therapeutics, INC. Verbesserte verfahren und zusammensetzungen zur wundheilung
WO2008094597A2 (en) * 2007-01-30 2008-08-07 University Of Georgia Research Foundation, Inc. Early mesoderm cells, a stable population of mesendoderm cells that has utility for generation of endoderm and mesoderm lineages and multipotent migratory cells (mmc)
US9080145B2 (en) 2007-07-01 2015-07-14 Lifescan Corporation Single pluripotent stem cell culture
JP2010532172A (ja) 2007-07-01 2010-10-07 ライフスキャン・インコーポレイテッド 単細胞の分化万能性幹細胞の培養
AU2008273813B2 (en) * 2007-07-12 2013-06-13 Compugen Ltd. Bioactive peptides and method of using same
US20100255580A1 (en) 2007-07-18 2010-10-07 Lifesccan, Inc. Differentiation of Human Embryonic Stem Cells
CN101952415B (zh) 2007-07-31 2017-06-27 生命扫描有限公司 人胚胎干细胞的分化
CN107574142B (zh) * 2007-11-27 2021-07-06 生命扫描有限公司 人胚胎干细胞的分化
CA2710375A1 (en) * 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Treatment of orthopedic conditions
US20110130710A1 (en) * 2007-12-21 2011-06-02 David Lawrence Becker Treatment of abnormal or excessive scars
CA2710386A1 (en) 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Improved medical devices
CN105886459A (zh) * 2008-02-21 2016-08-24 詹森生物科技公司 用于细胞粘附、培养和分离的方法、表面改性培养板和组合物
US8623648B2 (en) 2008-04-24 2014-01-07 Janssen Biotech, Inc. Treatment of pluripotent cells
CA2729121C (en) 2008-06-30 2019-04-09 Centocor Ortho Biotech Inc. Differentiation of pluripotent stem cells
RU2497490C2 (ru) * 2008-07-07 2013-11-10 Лаборатуар Медидом С.А. Заживляющая раневая повязка, снижающая температуру
US20110305672A1 (en) 2008-07-25 2011-12-15 University Of Georgia Research Foundation, Inc. COMPOSITIONS FOR MESODERM DERIVED ISL1+ MULTIPOTENT CELLS (IMPs), EPICARDIAL PROGENITOR CELLS (EPCs) AND MULTIPOTENT CD56C CELLS (C56Cs) AND METHODS OF PRODUCING AND USING SAME
CN102165058B (zh) 2008-07-25 2015-07-01 佐治亚大学研究基金会 中胚层来源的ISL 1+多潜能细胞(IMPs)的组合物、心外膜祖细胞(EPCs)和多潜能CXCR4+CD56+细胞(C56Cs)及其使用方法
US20100028307A1 (en) * 2008-07-31 2010-02-04 O'neil John J Pluripotent stem cell differentiation
JP2012507289A (ja) 2008-10-31 2012-03-29 ヤンセン バイオテツク，インコーポレーテツド ヒト胚性幹細胞の膵内分泌系への分化
AU2009308967C1 (en) 2008-10-31 2017-04-20 Janssen Biotech, Inc. Differentiation of human embryonic stem cells to the pancreatic endocrine lineage
CN102257132B (zh) * 2008-11-20 2014-09-03 森托科尔奥索生物科技公司 用于在平面基底上进行细胞附着和培养的方法和组合物
MX2011005288A (es) 2008-11-20 2011-06-01 Centocor Ortho Biotech Inc Celulas madre pluripotentes en microportadores.
ES2693088T3 (es) 2009-07-20 2018-12-07 Janssen Biotech, Inc. Diferenciación de células madre embriónicas humanas
WO2011011349A2 (en) * 2009-07-20 2011-01-27 Centocor Ortho Biotech Inc. Differentiation of human embryonic stem cells
JP6219568B2 (ja) 2009-07-20 2017-10-25 ヤンセン バイオテツク，インコーポレーテツド ヒト胚性幹細胞の分化
CN107058389A (zh) * 2009-10-29 2017-08-18 詹森生物科技公司 多能干细胞
DE202009017772U1 (de) * 2009-12-10 2011-04-21 Orthogen Ag Kombinationspräparate mit Cytokin-Antagonist und Corticosteroid
RU2586506C2 (ru) 2009-12-23 2016-06-10 Янссен Байотек, Инк. Дифференцировка человеческих эмбриональных стволовых клеток
BR112012017761A2 (pt) 2009-12-23 2015-09-15 Centocor Ortho Biotech Inc diferenciação das células-tronco embrionárias humanas
US9969981B2 (en) 2010-03-01 2018-05-15 Janssen Biotech, Inc. Methods for purifying cells derived from pluripotent stem cells
MX351515B (es) 2010-05-12 2017-10-17 Janssen Biotech Inc Diferenciacion de celulas madre embrionarias humanas.
KR20130100122A (ko) 2010-08-12 2013-09-09 얀센 바이오테크 인코포레이티드 췌장 내분비 전구 세포를 이용한 당뇨병의 치료
RU2599420C2 (ru) 2010-08-31 2016-10-10 Янссен Байотек, Инк. Дифференцирование плюрипотентных стволовых клеток
ES2658146T3 (es) 2010-08-31 2018-03-08 Janssen Biotech, Inc. Diferenciación de células madre embrionarias humanas
BR112013004616A2 (pt) 2010-08-31 2016-07-05 Janssen Biotech Inc diferenciação das células tronco embrionárias humanas
US9404087B2 (en) 2010-12-15 2016-08-02 Kadimastem Ltd. Insulin producing cells derived from pluripotent stem cells
KR102090751B1 (ko) 2011-12-22 2020-03-19 얀센 바이오테크 인코포레이티드 인간 배아 줄기 세포의 단일 인슐린 호르몬 양성 세포로의 분화
WO2013134378A1 (en) 2012-03-07 2013-09-12 Janssen Biotech, Inc. Defined media for expansion and maintenance of pluripotent stem cells
DK3450542T3 (da) 2012-06-08 2021-11-01 Janssen Biotech Inc Differentiering af humane embryonale stamceller til endokrine pancreatiske celler
SG11201505112SA (en) 2012-12-31 2015-07-30 Janssen Biotech Inc Differentiation of human embryonic stem cells into pancreatic endocrine cells using hb9 regulators
US10370644B2 (en) 2012-12-31 2019-08-06 Janssen Biotech, Inc. Method for making human pluripotent suspension cultures and cells derived therefrom
RU2018116647A (ru) 2012-12-31 2018-10-24 Янссен Байотек, Инк. Культивация эмбриональных стволовых клеток человека в воздушно-жидкостной зоне взаимодействия с целью их дифференцировки в панкреатические эндокринные клетки
CN105705634A (zh) 2012-12-31 2016-06-22 詹森生物科技公司 用于分化成胰腺内分泌细胞的人多能细胞的悬浮和群集
WO2014159662A1 (en) 2013-03-13 2014-10-02 University Of Miami Method for isolation and purification of microvesicles from cell culture supernatants and biological fluids
RU2694311C2 (ru) 2014-05-16 2019-07-11 Янссен Байотек, Инк. Применение малых молекул для увеличения экспрессии mafa в панкреатических эндокринных клетках
CA2958879A1 (en) 2014-08-22 2016-02-25 Auckland Uniservices Limited Channel modulators
WO2017094001A1 (en) 2015-11-30 2017-06-08 Kadimastem Ltd Methods for differentiating and purifying pancreatic endocrine cells
MA44236A (fr) * 2016-02-17 2018-12-26 Novartis Ag Anticorps anti-tgfbêta 2
MA45479A (fr) 2016-04-14 2019-02-20 Janssen Biotech Inc Différenciation de cellules souches pluripotentes en cellules de l'endoderme de l'intestin moyen
KR20230074475A (ko) 2020-08-21 2023-05-30 더 유니버시티 오브 마이애미 골수-유래 중간엽 줄기 세포로부터의 미세소포를 사용한 치료의 조성물 및 방법
US20230390341A1 (en) 2022-04-19 2023-12-07 University Of Miami Methods and compositions for prevention and treatment of graft versus host disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5155214A (en) * 1984-03-05 1992-10-13 The Salk Institute For Biological Studies Basic fibroblast growth factor
GB8823649D0 (en) * 1988-10-07 1988-11-16 Geistlich Soehne Ag Chemical compounds
IE61346B1 (en) * 1988-11-02 1994-11-02 Genentech Inc A permeable material to fit around the teeth or gums of a mammal
GB8927546D0 (en) 1989-12-06 1990-02-07 Ciba Geigy Process for the production of biologically active tgf-beta
WO1991010727A1 (en) 1990-01-22 1991-07-25 La Jolla Cancer Research Foundation Inhibitors of cell regulatory factors
GB9106678D0 (en) * 1991-03-28 1991-05-15 Ferguson Mark W J Wound healing

Also Published As

Publication number Publication date
CA2131383A1 (en) 1993-10-14
AU3762393A (en) 1993-11-08
DE69332624D1 (de) 2003-02-13
US6331298B1 (en) 2001-12-18
JP2005290009A (ja) 2005-10-20
AU673161B2 (en) 1996-10-31
ATE230605T1 (de) 2003-01-15
JP3919212B2 (ja) 2007-05-23
WO1993019769A1 (en) 1993-10-14
ES2189790T3 (es) 2003-07-16
SK116894A3 (en) 1995-02-08
EP0646012A1 (de) 1995-04-05
HUT68905A (en) 1995-08-28
NO943466D0 (no) 1994-09-16
PT646012E (pt) 2003-03-31
GB9206861D0 (en) 1992-05-13
JPH07505378A (ja) 1995-06-15
EP0646012B1 (de) 2003-01-08
DK0646012T3 (da) 2003-03-03
NZ249937A (en) 1996-09-25
HU9402771D0 (en) 1995-01-30
CA2131383C (en) 2002-07-16
RU94042387A (ru) 1996-11-10
NO943466L (no) 1994-09-16
BR9306226A (pt) 1996-12-03
CZ236694A3 (en) 1995-04-12

Similar Documents

Publication Publication Date Title
DE69332624T2 (de) WUNDHEILMITTEL UND BEHANDLUNG VON FIBROTISCHEN STORUNGEN DURCH TGFbeta-3
DE3687099T2 (de) Verwendung von einem cartilago-induzierenden faktor (cif) zur herstellung eines arzneimittels zur behandlung von entzuendungen.
DE69616376T2 (de) Verwendung von Tiagabin zur Behandlung von Schlafstörungen
ATE213411T1 (de) Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen
DE69636085D1 (de) Verwendung von gamma-Linolensäure oder Dihomogammalinolensäure zur Herstellung eines Medikaments zur Behandlung von Huntington's Chorea
DE69631478D1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
DE69424777D1 (de) 3,4-diarylchromane zur behandlung von dermatitis
DE69617729D1 (de) Verwendung von antimineralcorticoidverbindungen gegen das drogenentzugssyndrom
DE69210654T2 (de) Verwendung von Tomoxetine zur Behandlung von Funktionsstörungen der niedrigen Harnwege
ATE196738T1 (de) Verwendung von immunglobulin-präparationen zur herstellung eines medikaments zur oralen verabreichung zur behandlung und prophylaxe chronischer schmerzzustände
DE69635754D1 (de) Medikamente zur verhinderung von eingriffsbedingter stenose als folge von nicht-bypass invasiver eingriffe
ATE225177T1 (de) Verwendung von (+)mefloquine zur behandlung von malaria
DE69304843T2 (de) Methode zur Behandlung von Haarausfall
DE59107536D1 (de) Arzneimittel zur behandlung von hyperlipidämie und/oder atherosklerose
NO179245C (no) Arylalkylestere av 4,5-dihydroksy-9,10-dihydro-9,10-diokso-2-antracenkarboksylsyre med terapeutisk aktivitet
ES2159294T3 (es) Metodo y composicion para el tratamiento de la caida del cabello.
ATE178336T1 (de) Verwendung einer therapeutischen zusammensetzung zur behandlung von bronchitis
DE69732851D1 (de) Verwendung von dextrinsulfat zur behandlung von sehr vasculären tumoren
RU93027489A (ru) Способ хирургической коррекции хронических нарушений дуоденальной проходимости
DE69218544D1 (de) Verwendung von BMY 14802 zur Behandlung von Angstzuständen bei Patienten mit Benzodiazepin-Entzugserscheinungen
RU2001101468A (ru) Применение оптически чистого (-)норцисаприда для лечения апноэ, булимии и других расстройств
YU15301A (sh) PRIMENA R (+)- alfa-(2,3-DIMETOKSIFENIL)-1-[2-(4-FLUOROFENIL) ETIL] -4-PIPERIDINMETANOLA ZA LECENJE POREMEĆAJA SPAVANJA
RU94002713A (ru) Способ лечения детей с синдромом удлиненного интервала qт (романо-уорда)
DE68906028D1 (de) Verwendung von acetyl-d-carnitin zur therapeutischen behandlung von glaukom.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition